Journals / Sakarya Tıp Dergisi / 2019 / Cilt: 9 - Sayı: 1

Autotransplantation of Cryopreserved/Thawed Ovarian Tissue: Overview of Methods and Challenges

Pages
1–10
Publication Date
2019-03-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Even though the risk of reimplanting pre-existing cancer cells through ovarian transplantation is minimal or non-existent for most types of cancer, this risk must be ascertained according to cancer type and disease stage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In recent years, an increasing number of women diagnosed with malignant or non-malignant diseases have been subjected to cytotoxic chemoradiotherapy.
📊
Key Findings & Data:Despite its advantages, this fertility preservation method for women at risk of losing reproductive function is considered experimental due to 1) a possible decrease in the ovarian follicular pool as a result of cryopreservation and thawing procedures (although this has been minimised by improved methods), or by ischemic damage occurring during ovarian transplantation; and 2) the risk of minimal residual disease (which is the most important factor).
💡
Conclusion & Impact:Even though the risk of reimplanting pre-existing cancer cells through ovarian transplantation is minimal or non-existent for most types of cancer, this risk must be ascertained according to cancer type and disease stage.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Human · ovary · cryopreservation

Özet

In recent years, an increasing number of women diagnosed with malignant or non-malignant diseases have been subjected to cytotoxic chemoradiotherapy. Women who face the possibility of premature or imminent ovarian failure caused by cytotoxic therapy may retain their fertility potential via ovarian tissue cryopreservation. Despite its advantages, this fertility preservation method for women at risk of losing reproductive function is considered experimental due to 1) a possible decrease in the ovarian follicular pool as a result of cryopreservation and thawing procedures (although this has been minimised by improved methods), or by ischemic damage occurring during ovarian transplantation; and 2) the risk of minimal residual disease (which is the most important factor). Although the indications for ovarian cryopreservation now extend beyond cancer, cancer survivors remain as the patient population who most commonly need this procedure. For these patients, the risk of minimal residual disease, which can be defined as reintroducing pre-existing cancer cells, is an important challenge for the application of this method. Even though the risk of reimplanting pre-existing cancer cells through ovarian transplantation is minimal or non-existent for most types of cancer, this risk must be ascertained according to cancer type and disease stage.

🔖

Cite This Article

AYİK, H., EROL, Y. G., AYDİN, A. (2019). Autotransplantation of Cryopreserved/Thawed Ovarian Tissue: Overview of Methods and Challenges. Sakarya Tıp Dergisi, Cilt: 9 - Sayı: 1, 1–10. https://ajindex.com/articles/261603

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. American Cancer Society. Special section: obesity. Cancer Facts and Figures 2001. 1st ed. Atlanta GA: National Media Office; 2001. p.20-7
  2. Blatt J. Pregnancy outcomes in long-term survivors of childhood cancer. Med Pediatr Oncol 1999; 33:29-33
  3. Bedaiwy MA, Shahin AY, Falcone T. Reproductive organ transplantation: advances and controversies. Fertil Steril 2008; 90:2031-55
  4. Howell SJ, Sharlet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 2002; 4:443-52
  5. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005; 83:1622-8
  6. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364:1405-10
  7. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353:318-21
  8. Torre A, Vertu-Ciolino D, Mazoyer C, Selva J, Lornage J, Salle B. Safeguarding fertility with whole ovary cryopreservation and microvascular transplantation: Higher follicular survival with vitrification than with slow freezing in a ewe model. Transplantation. 2016;100(9):1889-97
  9. Oktay K, Aydin BA, Karlikaya G. A technique for laparoscopic transplantation of frozen banked ovarian tissue. Fertil Steril 2001; 75:1212-6
  10. Oktay K, Aydın BA, Economos K, et al. Restoration of ovarian function after autologous transplantation of human ovarian tissue in the forearm (Abstract). Fertil Steril 2000; 74:S90
  11. Dittrich R, Lotz L, Keck G, et al. Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertil Steril. 2012; 97:387-90
  12. Donnez J, Silber S, Andersen CY, et al. Children born after autotransplantation of cryopreserved ovarian tissue. A review of 13 live births. Ann Med. 2011; 43:437-5 0
  13. Revel A, Laufer N, Ben MA, et al. Micro-organ ovarian transplantation enables pregnancy: a case report. Hum Reprod. 2011; 26:1097-103
  14. Silber SJ. Ovary cryopreservation and transplantation for fertility preservation. Mol Hum Reprod. 2012; 18:59-67
  15. Andersen CY, Silber SJ, Bergholdt SH, et al. Long-term duration of function of ovarian tissue transplants: case reports. Reprod Biomed Online. 2012; 25:128-32
  16. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transp